Dechra Veterinary Products has unveiled a new update of Equipalazone

Dechra Veterinary Products has unveiled a new update of Equipalazone, for the treatment of a range of musculoskeletal disorders in ponies and horses, in an apple-flavoured presentation, as well as the usual product, which will be rebranded as Equipalazone Original.

Equipalazone contains analgesic NSAID phenylbutazone, widely used by vets for the treatment of lameness in horses and can be prescribed as a treatment for OA conditions, chronic and acute laminitis, carpitis and bursitis, as well as to minimise post-surgical soft tissue reaction.

Dechra’s apple-flavoured Equipalazone, which continues to be the only sugar-free phenylbutazone powder on the market, maintains its Microcaps technology and is available for dispensing in lightweight one-point-five gramme pouches that are added to the feed.

Emma Jennings, Dechra brand manager, stated: “The new apple flavoured Equipalazone is the same tried and trusted popular product that vets have been using for many years, but the enhanced apple flavour should improve compliance among even the fussiest of feeders. Equipalazone has been a best selling treatment delivering powerful pain relief since we brought it to the market as the first microencapsulated phenylbutazone more than forty-five years ago. The apple-flavoured presentation will give vets even more choice when it comes to providing pain relief and anti-inflammatory treatment for equine conditions.”